Navigation Links
CeNeS Pharmaceuticals plc: Update on Successful Phase III results,announced on Lead Product M6G

Further analysis of Phase III trial data underlines M6G's benefit compared to morphine in the treatment of post-operative pain

CAMBRIDGE, England, 7th March 2007 - CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces additional data from the pivotal Phase III trial (M6G022) of M6G (morphine-6-glucuronide) in over 500 patients with post-operative pain. The preliminary data released on 20th February showed that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV).

Secondary Data Results

The additional secondary data now received by CeNeS shows that:

* less anti-emetic drugs (drugs used to control nausea and vomiting) were required in patients treated with M6G compared with those on morphine; and * M6G exhibited a long duration of analgesic action.

This was the first Phase III study where patients were given a complete pain management programme with M6G (rapid titration to comfort followed by PCA for up to 48 hours) and the first Phase III trial where nausea and vomiting were assessed as primary endpoints.

Management of PONV/use of anti-emetics

In addition to the clear nausea and vomiting reductions of over 25% announced last week, secondary data reveals that patients receiving M6G required over 20% less anti-emetic medication over the 0-24 hour period than those in the morphine group. This shows that not only does M6G induce significantly less nausea and vomiting than morphine, but also that the post-operative anti-emetic treatment required is considerably reduced.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assistance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

Drug consumption

It has been sh own in previous studies that the dose of M6G required to provide analgesia immediately after surgery is three times that of morphine. In accordance with this, the M6G022 trial was designed such that M6G was available in a 3:1 ratio to morphine during the titration to comfort phase. Thereafter pain relief was provided using patient controlled analgesia (PCA) in a dose ratio of 2:1 (M6G:morphine). The secondary data announced today demonstrated again that in the initial phase after surgery the dose of M6G required to titrate patients to comfort was 3 times that required for morphine on a weight basis. However, during the prolonged PCA phase, the ratio was lower (0-24 hours 1.6:1; 24-48 hours 1.4:1). This shows that patients in the M6G group made less demands for pain relief after titration to comfort, as assessed by presses on the PCA button. These data support the hypothesis that M6G has a longer duration of analgesic action than morphine.


The M6G022 data shows that M6G patients experience lower levels of sedation compared to those on morphine for up to 48 hours. This is another advantage of M6G that has been indicated from previous clinical data and adds to the considerable package of potential benefits to patients and clinicians. The M6G patients also showed no adverse cardiovascular effects which again supports CeNeS claims that M6G has a very good safety profile.

Partnering strategy

There is a clear need for new drugs that can improve the quality of pain management currently given to patients by standard morphine regimens across the world and M6G is well positioned to address that market. Since the announcement of the successful data last week significant interest has been expressed by Pharma companies in reviewing the large M6G data package that CeNeS has assembled. CeNeS is confident that agreements can be finalised with partner(s) based on the existing set of clinical trial data. Concluding these deals will generate short term income and recurring revenue streams from a successful product launch in the future.

Regulatory strategy

CeNeS preferred strategy is for a partner to be involved in the key decisions regarding regulatory filing strategies both in Europe and in United States. The strategy in the USA is clear. The strong data obtained from the most recent Phase III study validates the proposed product profile of M6G and strengthens CeNeS position with potential North American partners. Registration could be achieved in the USA in 2009 after conducting two Phase III studies to the requirements of the FDA. It is important to note that the quality and robustness of the clinical data produced by the current study significantly reduces the risk for the development of M6G by enabling optimal trial design and the selection of endpoints in the remaining Phase III studies.

In Europe the narrow failure to achieve statistical significance with the second chosen primary endpoint of incidence and severity of nausea (p=0.052 not p<0.050) offers three options:

1) Pursue a filing application in certain European countries with the comprehensive clinical data package that CeNeS has assembled. 2) Further strengthen the European package by conducting an additional European Phase III study which would complete in 2008 with product filing in 2009. 3) Use the USA Phase III trials to support the European application, potentially with a global partner.

CeNeS will continue to discuss the above strategies with regulatory consultants and potential partners.

Neil Clark, Chief Executive of CeNeS commented "The ongoing analysis of the Phase III results further confirms our belief in the excellent potential of M6G as a novel product for post- operative pain. The quality and breadth of the data contained in this large study supports M6G's anticipated product profile.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assi stance and the improved patient comfort due to lower PONV supports CeNeS justification of a substantial price premium for M6G compared to morphine.

We are actively pursuing potential partners for M6G and are confident that agreements can be reached. We are well positioned to deliver significant value to shareholders by the successful commercialisation of M6G".

- END -

CeNeS Pharmaceuticals plc will be announcing its preliminary results for the year ended 31 December 2006 on Wednesday 28 March 2007. On the same day the Company will be hosting an R&D presentation at the offices of Financial Dynamics. The presentation will start at 9:30am and is expected to conclude at 11am.

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site:

About M6G Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

The active potent metabolite of morphine, morphine-6-glucuronide (M6G), may offer therapeutic advantages over morphine in having an equivalent analgesic effect, but with a reduced tendency to cause nausea, vomiting and respiratory depression. Phase II and III clinical trials have sho wn that M6G given intravenously produces equivalent analgesia to morphine to combat post-operative pain. Studies have also shown that M6G reduced the incidence of nausea and vomiting when compared directly with morphine. Other studies published recently in the scientific literature demonstrate that M6G also reduces respiratory depression compared to morphine.

The global market for opiate use in managing post-operative pain was estimated at $1 billion in 2000 and growing at a rate of 6-7%.

Summary of Phase III trial (M6G022) results

1. M6G matches morphine for analgesic effect

Importantly for a novel pain product, the trial results unequivocally show that M6G is as good as morphine in terms of analgesia achieved in patients up to 48 hours post-operatively. Successful achievement of this first primary endpoint supports data from previous clinical trials of M6G and is an essential component in the product profile of M6G.

2. M6G shows significant reduction in post-operative nausea and vomiting compared to morphine

The trial results confirm the excellent potential of M6G as an analgesic with a clinically significant improved side effect profile compared to morphine. The study results show that patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24 hours after treatment (statistically significant, p=0.018).

In addition, the incidence of dry retching/vomiting in the M6G arm compared to the morphine arm in the 24 hour period after treatment was reduced by 32% ( statistically significant, p= 0.044). The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observed in the morphine arm in the period 6 - 24 hours after treatment. This was the second primary endpoint and approached statistical significance (p=0.052).

Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operat ive pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

M6G's lower propensity to cause nausea and vomiting in the post-operative period strongly supports CeNeS' belief in the potential of M6G as a novel product for the treatment of post-operative pain with clear advantages over morphine.

3. Safety profile/adverse events

The trial confirmed that M6G's safety profile is similar to morphine. Aside from nausea and vomiting, the adverse events reported were at levels similar to those experienced by patients receiving morphine in a post-operative setting.

M6G022 Study Design The study involved 24 centres in six European countries and recruited 517 patients. The study was designed primarily to provide key information on a comparison of effective intravenous pain management regimens of M6G or morphine treatment for a minimum of 24 hours (and up to 48 hours) following major abdominal surgery. Morphine is generally accepted as the "gold standard" drug for use in these circumstances. Initial pain management was achieved by administration of a loading dose and titration of either M6G or morphine to achieve acceptably low levels of pain for the patient to go onto the ward. In the ward, pain management treatment was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- Treatment with either M6G or morphine, particularly during PCA, results in similar levels of pain management; and

- Effective analgesic treatment during PCA results i n lower levels of nausea and vomiting in patients receiving M6G compared to those receiving morphine.

In addition, other important side effect, efficacy and safety features were determined throughout the study.


Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals Plc Announces Preliminary Results for The Year Ending 31 December 2006
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:10/9/2015)... October 9, 2015 ... The report summarizes key statistics ... status of the manufacturers making it ... direction for companies and individuals interested ... . --> ...
(Date:10/9/2015)... N.Y. , Oct. 9, 2015 ... world,s largest provider of health care products and services ... reminded its customers that the Henry Schein Disaster Relief ... experience operational, logistical or financial issues as a result ... . The toll-free number for all Henry ...
(Date:10/9/2015)... 9, 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical study of telotristat etiprate has been accepted for ... to be held from October 15-17, in Austin, ... who completed the randomized treatment portion of the TELESTAR study ... session. --> --> Telotristat ...
Breaking Medicine Technology:
... , SARASOTA, Fla., Nov. 6 Roper Industries, ... it has signed a definitive agreement to acquire Verathon, ... The Verathon Board of Directors has approved the transaction ... and closing conditions, including shareholder approval. The parties ...
... Companies (ASMC), an informal working group of mid-market and ... 3962, the "Affordable Health Care for America Act," introduced ... fear that the cumulative effect of a host of ... bring new medicines to market. , From ...
Cached Medicine Technology:
(Date:10/9/2015)... Beach, CA (PRWEB) , ... October 09, 2015 ... ... is now offering a special promotion on Invisalign, the orthodontic system that uses ... reasons. The aligners are almost invisible against the teeth, which allow patients to ...
(Date:10/9/2015)... ... October 09, 2015 , ... On Saturday, September 26, ... Jump Rope Championship in Madrid, Spain. Representing both the USA and Sweden in the ... Unders and One-Minute Am Front Crosses, she was awarded 1 Silver and 4 Gold ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... New Orleans and the surrounding communities, is initiating a combined charity effort with ... for unwanted animals in southern Louisiana. , Animal Rescue New Orleans is ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... upcoming episode of Innovations with Ed Begley Jr., airing 1st QT 2016 via ... will educate audiences on MMJ Phytotech Limited (MMJ) – a global leader in ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... oldest and largest recreational dispensaries in Colorado, says the latest figures on the ... rapidly and maturing into a legitimate industry. , Last month, according to ...
Breaking Medicine News(10 mins):
... of Medicine (BUSM) have found that some medical inpatients ... intervention. The BUSM study appears in the May issue ... . , "Brief intervention shows promise for increasing receipt ... cognitive functioning or an alcohol- attributable diagnosis," said lead ...
... on human genome , , THURSDAY, April 23 (HealthDay News) -- ... has succeeded in sequencing the entire genome of the placid, ... biology of this bovine and related creatures (even humans), and ... two reports in the April 24 issue of Science ...
... Harvard Medical School today announced the launch ... cancer and other prostate conditions understand the issues related ... treatment. The website, , was ... medical oncology and urologic cancer. This website is especially ...
... Keeping Michigan Workers Working!LANSING, Mich., April 23 May ... MICHIGAN will hold a summit involving 120 of Michigan,s ... Workability in Michigan, , ... professions and organizations who are passionate about promoting safer, ...
... MR procedure that uses diffusion-weighted imaging (DWI) to determine ... benign may help reduce unnecessary breast biopsies, according to ... in Bethesda, MD. DWI is a method that produces ... compartments (diffusion). , The study included 80 patients ...
... tubo ovarian abscesses help women avoid surgery, according to ... MA. Tubo ovarian abscesses (TOAs) are an infected collection ... They can occur in patients with complicated cases of ... study included 54 TOAs in 46 patients. Results showed ...
Cached Medicine News:
... Sensor Intravascular Mikro-Tip Pressure Catheters; Millar ... dual pressure sensor catheters for simultaneous ... are suitable for measuring pressure gradients ... across a vascular stenosis. The catheters ...
... the United States dying from Sudden Cardiac Death ... recommended that AEDs be used as a standard ... Any AED can provide a life-saving shock during ... continuous monitoring capabilities during and after resuscitation. Plus ...
... These catheters are indicated ... soft emboli and thrombi from ... These catheters may also be ... blood vessels, infusion of fluids, ...
... catheter is designed to remove thrombus ... saline jets travel backwards at half ... a low pressure zone causing a ... the catheter where it is fragmented ...
Medicine Products: